Clinical Trials
Positive Dupilumab Topline Results From Phase 3 Trial In Uncontrolled Persistent Asthma Announced By Regeneron And Sanofi
Regeneron Pharmaceuticals, Inc. and Sanofi announced that the pivotal Phase 3 LIBERTY ASTHMA QUEST study of dupilumab in a broad population of patients with uncontrolled, persistent asthma met its two primary endpoints. Dupilumab, when added to...
Clinical Trials
Presented in VIVA Late Breaking Clinical Trials Medtronic IN.PACT Admiral DCB Global Two Year Data and IN.PACT SFA Four Year Data
Medtronic plc data announced reinforce the durability and safety of the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The two-year, real-world results from the full clinical cohort of the IN.PACT Global...
Clinical Trials
License Expansion for RGN-137 in Europe, S. Korea, Japan, Canada and Australia Completed By RegeneRX
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration announced that it has completed a license expansion agreement with GtreeBNT for the rights to RGN-137, RegeneRx's topical...
Clinical Trials
Blake Insomnia Therapeutics Inc. Announces Submitting Clinical Trial Application for Phase II Clinical Testing
Blake Insomnia Therapeutics Inc. , a New York based pharmaceutical company devoted to improving quality of life for people with insomnia, is excited to announce it has submitted its clinical trial application for Phase II clinical testing to Health...
Clinical Trials
Titan pharmaceuticals receives fda clearance to begin clinical study of parkinson’s disease treatment
Titan Pharmaceuticals, Inc. announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for its ropinirole implant intended for treatment of the signs and symptoms of Parkinson's disease. The Phase 1/2 clinical study...
Clinical Trials
Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Osteoarthritis
Symic Bio, a biopharmaceutical company developing novel matrix regulators,announced the treatment of the first patient in the MODIFY2 Phase 2 clinical trial investigating SB-061 for pain management in mild-to-moderate osteoarthritis of the knee. The initiation of...
Articles
Driving Patient Engagement in Alzheimer’s Disease Clinical Research to Achieve Trial Success
Worldwide, around 47 million people have dementia, and there are 9.9 million new cases every year, according to recent data from the World Health Organization (WHO)1.Alzheimer's disease (AD) is the most common cause of dementia and may contribute to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
